| Phospholipid nanosomes. | |
| | |
MedLine Citation:
|
PMID: 16305436 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Phospholipid nanosomes are small, uniform liposomes manufactured utilizing supercritical fluid technologies. Supercritical fluids are first used to solvate phospholipid raw materials, and then decompressed to form phospholipid nanosomes that can encapsulate hydrophilic molecules such as proteins and nucleic acids. Hydrophobic therapeutics are co-solvated with phospholipid raw materials in supercritical fluids that, when decompressed, form phospholipid nanosomes encapsulating these drugs in their lipid bilayers. Mathematical modeling and semi-empirical experiments indicate that the size and character of phospholipid nanosomes depend on the several process parameters and material properties including the size and design of decompression nozzle, bubble size, pressure and the rate of decompression, interfacial forces, charge distribution and the nature of compound being encapsulated. Examples are presented for the encapsulation of a protein and hydrophobic drugs. In vitro and in vivo data on breast cancer cells and xenografts in nude mice indicate that paclitaxel nanosomes are less toxic and much more effective than paclitaxel in Cremophor EL (Taxol). Camptothecin nanosomes demonstrate that the normally very water-insoluble camptothecin can be formulated in a biocompatible aqueous medium while retaining in vivo efficacy against lymphoma xenografts in nude mice. In vitro data for betulinic acid nanosomes demonstrate enhanced efficacy against HIV-1 (EC50 of 1.01 microg/ml versus 6.72 microg/ml for neat betulinic acid). Phospholipid nanosomes may find utility in the enhanced delivery of hydrophilic drugs such as recombinant proteins and nucleic acid as well as hydrophobic anticancer and anti-HIV drugs. |
| | |
Authors:
|
Trevor P Castor |
Related Documents
:
|
4576016 - Metabolism of membrane phospholipids and its relation to a novel class of oligosacchari... 4290406 - Chromatographic behaviour of rat-liver monophosphoinositide. 2852256 - Proton conductance caused by long-chain fatty acids in phospholipid bilayer membranes. 3729966 - Effect of ethanol intake on human erythrocyte membrane fluidity and lipid composition. 8100096 - Is l-dopa an endogenous neurotransmitter? 6811706 - The influence of excess lysine on urea cycle operation and pyrimidine biosynthesis. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review |
Journal Detail:
|
Title: Current drug delivery Volume: 2 ISSN: 1567-2018 ISO Abbreviation: - Publication Date: 2005 Oct |
Date Detail:
|
Created Date: 2005-11-24 Completed Date: 2005-12-15 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 101208455 Medline TA: Curr Drug Deliv Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 329-40 Citation Subset: IM |
Affiliation:
|
Aphios Corporation, 3-E Gill Street, Woburn, MA 01801, USA. tcastor@aphios.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Agents, Phytogenic / administration & dosage Camptothecin / administration & dosage Chromatography, Supercritical Fluid Drug Compounding Drug Industry Humans Nanotubes* Paclitaxel / administration & dosage Phospholipids / administration & dosage*, chemistry Solvents Triterpenes / administration & dosage |
| Grant Support | |
ID/Acronym/Agency:
|
1R43-CA-58140/CA/NCI NIH HHS; N43-CM-17019/CM/NCI NIH HHS; N44-CM-27122/CM/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Phytogenic; 0/Phospholipids; 0/Solvents; 0/Triterpenes; 33069-62-4/Paclitaxel; 472-15-1/betulinic acid; 7689-03-4/Camptothecin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lipid-core micelles for targeted drug delivery.
Next Document: The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combi...